UBE2C and prostate carcinoma: Post-translational modification of Mediator 1(MED1) T1032 phosphorylation, which was regulated by PI3K/AKT signaling pathway [41], promoted the expression of UBE2C in prostate cancer and enhanced the role of UBE2C in promoting the proliferation of prostate cancer and in driving prostate cancer progression.